HilleVax (Nasdaq: HLVX) has agreed terms for a licensing deal with Chengdu-based Kanghua Biological (SHE: 300841), a Chinese biotech also known as Kangh.
The agreement covers Kangh’s hexavalent virus-like particle (VLP) norovirus vaccine candidate, known as HIL-216, outside of China, Hong Kong, Taiwan and Macau.
HilleVax will pay Kangh an upfront payment of $15 million with the potential for additional payments of up to $256 million in milestones, plus single-digit tiered royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze